Top

Published in:

Open Access 01-12-2013 | Review

MEK and the inhibitors: from bench to bedside

Authors: Akintunde Akinleye, Muhammad Furqan, Nikhil Mukhi, Pavan Ravella, Delong Liu

Published in: Journal of Hematology & Oncology | Issue 1/2013

Abstract

Four distinct MAP kinase signaling pathways involving 7 MEK enzymes have been identified. MEK1 and MEK2 are the prototype members of MEK family proteins. Several MEK inhibitors are in clinical trials. Trametinib is being evaluated by FDA for the treatment of metastatic melanoma with BRAF V600 mutation. Selumetinib has been studied in combination with docetaxel in phase II randomized trial in previously treated patients with advanced lung cancer. Selumetinib group had better response rate and progression-free survival. This review also summarized new MEK inhibitors in clinical development, including pimasertib, refametinib, PD-0325901, TAK733, MEK162 (ARRY 438162), RO5126766, WX-554, RO4987655 (CH4987655), GDC-0973 (XL518), and AZD8330.

Available only for authorised users

Chang L, Karin M: Mammalian MAP kinase signalling cascades. Nature. 2001, 410 (6824): 37-40.PubMedCrossRef

Thompson N, Lyons J: Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Curr Opin Pharmacol. 2005, 5 (4): 350-356.PubMedCrossRef

Hsueh C-T, Liu D, Wang H: Novel biomarkers for diagnosis, prognosis, targeted therapy and clinical trials. Biomarker Res. 2013, 1 (1): 1-CrossRef

Furqan M, Mukhi N, Lee B, Liu D: Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application. Biomarker Res. 2013, 1 (1): 5-CrossRef

Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011, 364 (26): 2507-2516.PubMedCentralPubMedCrossRef

Lee B, Mukhi N, Liu D: Current management and novel agents for malignant melanoma. J Hematol Oncol. 2012, 5: 3-PubMedCentralPubMedCrossRef

Fischmann TO, Smith CK, Mayhood TW, Myers JE, Reichert P, Mannarino A, Carr D, Zhu H, Wong J, Yang RS: Crystal structures of MEK1 binary and ternary complexes with nucleotides and inhibitors. Biochemistry. 2009, 48 (12): 2661-2674.PubMedCrossRef

Takekawa M, Tatebayashi K, Saito H: Conserved docking site is essential for activation of mammalian MAP kinase kinases by specific MAP kinase kinase kinases. Mol Cell. 2005, 18 (3): 295-306.PubMedCrossRef

Liang H, Liu T, Chen F, Liu Z, Liu S: A full-length 3D structure for MAPK/ERK kinase 2 (MEK2). Sci China Life Sci. 2011, 54 (4): 336-341.PubMedCrossRef

10.

Sacks DB: The role of scaffold proteins in MEK/ERK signalling. Biochem Soc Trans. 2006, 34 (Pt 5): 833-836.PubMedCrossRef

11.

Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D: RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer. 2011, 11 (11): 761-774.PubMedCentralPubMedCrossRef

12.

Roskoski R: RAF protein-serine/threonine kinases: structure and regulation. Biochem Biophys Res Commun. 2010, 399 (3): 313-317.PubMedCrossRef

13.

Roovers K, Assoian RK: Integrating the MAP kinase signal into the G1 phase cell cycle machinery. Bioessays. 2000, 22 (9): 818-826.PubMedCrossRef

14.

Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR: Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 2000, 14 (19): 2501-2514.PubMedCentralPubMedCrossRef

15.

Hwang CY, Lee C, Kwon KS: Extracellular signal-regulated kinase 2-dependent phosphorylation induces cytoplasmic localization and degradation of p21Cip1. Mol Cell Biol. 2009, 29 (12): 3379-3389.PubMedCentralPubMedCrossRef

16.

Yang JY, Zong CS, Xia W, Yamaguchi H, Ding Q, Xie X, Lang JY, Lai CC, Chang CJ, Huang WC: ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol. 2008, 10 (2): 138-148.PubMedCentralPubMedCrossRef

17.

Balmanno K, Cook SJ: Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ. 2009, 16 (3): 368-377.PubMedCrossRef

18.

Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W: Mutations of the BRAF gene in human cancer. Nature. 2002, 417 (6892): 949-954.PubMedCrossRef

19.

Marks JL, Gong Y, Chitale D, Golas B, McLellan MD, Kasai Y, Ding L, Mardis ER, Wilson RK, Solit D: Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008, 68 (14): 5524-5528.PubMedCentralPubMedCrossRef

20.

Murugan AK, Dong J, Xie J, Xing M: MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas. Cell Cycle. 2009, 8 (13): 2122-2124.PubMedCrossRef

21.

Rampoldi L, Zimbello R, Bortoluzzi S, Tiso N, Valle G, Lanfranchi G, Danieli GA: Chromosomal localization of four MAPK signaling cascade genes: MEK1, MEK3, MEK4 and MEKK5. Cytogenet Cell Genet. 1997, 78 (3–4): 301-303.PubMedCrossRef

22.

Han J, Lee JD, Jiang Y, Li Z, Feng L, Ulevitch RJ: Characterization of the structure and function of a novel MAP kinase kinase (MKK6). J Biol Chem. 1996, 271 (6): 2886-2891.PubMedCrossRef

23.

Stein B, Brady H, Yang MX, Young DB, Barbosa MS: Cloning and characterization of MEK6, a novel member of the mitogen-activated protein kinase kinase cascade. J Biol Chem. 1996, 271 (19): 11427-11433.PubMedCrossRef

24.

Virtue A, Wang H, Yang X-f: MicroRNAs and Toll-like Receptor/Interleukin-1 Receptor Signaling. J Hematol Oncol. 2012, 5 (1): 66-PubMedCentralPubMedCrossRef

25.

Zarubin T, Han J: Activation and signaling of the p38 MAP kinase pathway. Cell Res. 2005, 15 (1): 11-18.PubMedCrossRef

26.

Brancho D, Tanaka N, Jaeschke A, Ventura JJ, Kelkar N, Tanaka Y, Kyuuma M, Takeshita T, Flavell RA, Davis RJ: Mechanism of p38 MAP kinase activation in vivo. Genes Dev. 2003, 17 (16): 1969-1978.PubMedCentralPubMedCrossRef

27.

Bulavin DV, Fornace AJ: p38 MAP kinase’s emerging role as a tumor suppressor. Adv Cancer Res. 2004, 92: 95-118.PubMedCrossRef

28.

Bulavin DV, Higashimoto Y, Popoff IJ, Gaarde WA, Basrur V, Potapova O, Appella E, Fornace AJ: Initiation of a G2/M checkpoint after ultraviolet radiation requires p38 kinase. Nature. 2001, 411 (6833): 102-107.PubMedCrossRef

29.

Iyoda K, Sasaki Y, Horimoto M, Toyama T, Yakushijin T, Sakakibara M, Takehara T, Fujimoto J, Hori M, Wands JR: Involvement of the p38 mitogen-activated protein kinase cascade in hepatocellular carcinoma. Cancer. 2003, 97 (12): 3017-3026.PubMedCrossRef

30.

Hanks SK, Quinn AM, Hunter T: The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science. 1988, 241 (4861): 42-52.PubMedCrossRef

31.

Kyriakis JM, Avruch J: Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev. 2001, 81 (2): 807-869.PubMed

32.

Eferl R, Ricci R, Kenner L, Zenz R, David JP, Rath M, Wagner EF: Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Cell. 2003, 112 (2): 181-192.PubMedCrossRef

33.

Ip YT, Davis RJ: Signal transduction by the c-Jun N-terminal kinase (JNK)–from inflammation to development. Curr Opin Cell Biol. 1998, 10 (2): 205-219.PubMedCrossRef

34.

Putcha GV, Le S, Frank S, Besirli CG, Clark K, Chu B, Alix S, Youle RJ, LaMarche A, Maroney AC: JNK-mediated BIM phosphorylation potentiates BAX-dependent apoptosis. Neuron. 2003, 38 (6): 899-914.PubMedCrossRef

35.

Tournier C, Hess P, Yang DD, Xu J, Turner TK, Nimnual A, Bar-Sagi D, Jones SN, Flavell RA, Davis RJ: Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science. 2000, 288 (5467): 870-874.PubMedCrossRef

36.

Deng X, Xiao L, Lang W, Gao F, Ruvolo P, May WS: Novel role for JNK as a stress-activated Bcl2 kinase. J Biol Chem. 2001, 276 (26): 23681-23688.PubMedCrossRef

37.

Xu P, Davis RJ: c-Jun NH2-terminal kinase is required for lineage-specific differentiation but not stem cell self-renewal. Mol Cell Biol. 2010, 30 (6): 1329-1340.PubMedCentralPubMedCrossRef

38.

Ganiatsas S, Kwee L, Fujiwara Y, Perkins A, Ikeda T, Labow MA, Zon LI: SEK1 deficiency reveals mitogen-activated protein kinase cascade crossregulation and leads to abnormal hepatogenesis. Proc Natl Acad Sci USA. 1998, 95 (12): 6881-6886.PubMedCentralPubMedCrossRef

39.

Nishina H, Bachmann M, Oliveira-dos-Santos AJ, Kozieradzki I, Fischer KD, Odermatt B, Wakeham A, Shahinian A, Takimoto H, Bernstein A: Impaired CD28-mediated interleukin 2 production and proliferation in stress kinase SAPK/ERK1 kinase (SEK1)/mitogen-activated protein kinase kinase 4 (MKK4)-deficient T lymphocytes. J Exp Med. 1997, 186 (6): 941-953.PubMedCentralPubMedCrossRef

40.

Choukroun G, Hajjar R, Fry S, del Monte F, Haq S, Guerrero JL, Picard M, Rosenzweig A, Force T: Regulation of cardiac hypertrophy in vivo by the stress-activated protein kinases/c-Jun NH(2)-terminal kinases. J Clin Invest. 1999, 104 (4): 391-398.PubMedCentralPubMedCrossRef

41.

Derijard B, Raingeaud J, Barrett T, Wu IH, Han J, Ulevitch RJ, Davis RJ: Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms. Science. 1995, 267 (5198): 682-685.PubMedCrossRef

42.

Jiang Y, Chen C, Li Z, Guo W, Gegner JA, Lin S, Han J: Characterization of the structure and function of a new mitogen-activated protein kinase (p38beta). J Biol Chem. 1996, 271 (30): 17920-17926.PubMedCrossRef

43.

Lin A, Minden A, Martinetto H, Claret FX, Lange-Carter C, Mercurio F, Johnson GL, Karin M: Identification of a dual specificity kinase that activates the Jun kinases and p 38–Mpk2. Science. 1995, 268 (5208): 286-290.PubMedCrossRef

44.

Cunningham SC, Gallmeier E, Hucl T, Dezentje DA, Calhoun ES, Falco G, Abdelmohsen K, Gorospe M, Kern SE: Targeted deletion of MKK4 in cancer cells: a detrimental phenotype manifests as decreased experimental metastasis and suggests a counterweight to the evolution of tumor-suppressor loss. Cancer Res. 2006, 66 (11): 5560-5564.PubMedCrossRef

45.

Nakayama K, Nakayama N, Davidson B, Katabuchi H, Kurman RJ, Velculescu VE, Shih Ie M, Wang TL: Homozygous deletion of MKK4 in ovarian serous carcinoma. Cancer Biol Ther. 2006, 5 (6): 630-634.PubMedCrossRef

46.

Hickson JA, Huo D, Vander Griend DJ, Lin A, Rinker-Schaeffer CW, Yamada SD: The p38 kinases MKK4 and MKK6 suppress metastatic colonization in human ovarian carcinoma. Cancer Res. 2006, 66 (4): 2264-2270.PubMedCrossRef

47.

English JM, Vanderbilt CA, Xu S, Marcus S, Cobb MH: Isolation of MEK5 and differential expression of alternatively spliced forms. J Biol Chem. 1995, 270 (48): 28897-28902.PubMedCrossRef

48.

Zhou G, Bao ZQ, Dixon JE: Components of a new human protein kinase signal transduction pathway. J Biol Chem. 1995, 270 (21): 12665-12669.PubMedCrossRef

49.

Chao TH, Hayashi M, Tapping RI, Kato Y, Lee JD: MEKK3 directly regulates MEK5 activity as part of the big mitogen-activated protein kinase 1 (BMK1) signaling pathway. J Biol Chem. 1999, 274 (51): 36035-36038.PubMedCrossRef

50.

Kamakura S, Moriguchi T, Nishida E: Activation of the protein kinase ERK5/BMK1 by receptor tyrosine kinases. Identification and characterization of a signaling pathway to the nucleus. J Biol Chem. 1999, 274 (37): 26563-26571.PubMedCrossRef

51.

Kato Y, Kravchenko VV, Tapping RI, Han J, Ulevitch RJ, Lee JD: BMK1/ERK5 regulates serum-induced early gene expression through transcription factor MEF2C. EMBO J. 1997, 16 (23): 7054-7066.PubMedCentralPubMedCrossRef

52.

Sun W, Kesavan K, Schaefer BC, Garrington TP, Ware M, Johnson NL, Gelfand EW, Johnson GL: MEKK2 associates with the adapter protein Lad/RIBP and regulates the MEK5-BMK1/ERK5 pathway. J Biol Chem. 2001, 276 (7): 5093-5100.PubMedCrossRef

53.

Nakamura K, Uhlik MT, Johnson NL, Hahn KM, Johnson GL: PB1 domain-dependent signaling complex is required for extracellular signal-regulated kinase 5 activation. Mol Cell Biol. 2006, 26 (6): 2065-2079.PubMedCentralPubMedCrossRef

54.

Akaike M, Che W, Marmarosh NL, Ohta S, Osawa M, Ding B, Berk BC, Yan C, Abe J: The hinge-helix 1 region of peroxisome proliferator-activated receptor gamma1 (PPARgamma1) mediates interaction with extracellular signal-regulated kinase 5 and PPARgamma1 transcriptional activation: involvement in flow-induced PPARgamma activation in endothelial cells. Mol Cell Biol. 2004, 24 (19): 8691-8704.PubMedCentralPubMedCrossRef

55.

English JM, Pearson G, Baer R, Cobb MH: Identification of substrates and regulators of the mitogen-activated protein kinase ERK5 using chimeric protein kinases. J Biol Chem. 1998, 273 (7): 3854-3860.PubMedCrossRef

56.

Kasler HG, Victoria J, Duramad O, Winoto A: ERK5 is a novel type of mitogen-activated protein kinase containing a transcriptional activation domain. Mol Cell Biol. 2000, 20 (22): 8382-8389.PubMedCentralPubMedCrossRef

57.

Terasawa K, Okazaki K, Nishida E: Regulation of c-Fos and Fra-1 by the MEK5-ERK5 pathway. Genes Cells. 2003, 8 (3): 263-273.PubMedCrossRef

58.

Kato Y, Tapping RI, Huang S, Watson MH, Ulevitch RJ, Lee JD: Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor. Nature. 1998, 395 (6703): 713-716.PubMedCrossRef

59.

Wang X, Tournier C: Regulation of cellular functions by the ERK5 signalling pathway. Cell Signal. 2006, 18 (6): 753-760.PubMedCrossRef

60.

Nishimoto S, Kusakabe M, Nishida E: Requirement of the MEK5-ERK5 pathway for neural differentiation in Xenopus embryonic development. EMBO Rep. 2005, 6 (11): 1064-1069.PubMedCentralPubMedCrossRef

61.

Regan CP, Li W, Boucher DM, Spatz S, Su MS, Kuida K: Erk5 null mice display multiple extraembryonic vascular and embryonic cardiovascular defects. Proc Natl Acad Sci USA. 2002, 99 (14): 9248-9253.PubMedCentralPubMedCrossRef

62.

Hu B, Ren D, Su D, Lin H, Xian Z, Wan X, Zhang J, Fu X, Jiang L, Diao D: Expression of the phosphorylated MEK5 protein is associated with TNM staging of colorectal cancer. BMC Cancer. 2012, 12: 127-PubMedCentralPubMedCrossRef

63.

Mehta PB, Jenkins BL, McCarthy L, Thilak L, Robson CN, Neal DE, Leung HY: MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion. Oncogene. 2003, 22 (9): 1381-1389.PubMedCrossRef

64.

Esparis-Ogando A, Diaz-Rodriguez E, Montero JC, Yuste L, Crespo P, Pandiella A: Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2. Mol Cell Biol. 2002, 22 (1): 270-285.PubMedCentralPubMedCrossRef

65.

Nagel S, Burek C, Venturini L, Scherr M, Quentmeier H, Meyer C, Rosenwald A, Drexler HG, MacLeod RA: Comprehensive analysis of homeobox genes in Hodgkin lymphoma cell lines identifies dysregulated expression of HOXB9 mediated via ERK5 signaling and BMI1. Blood. 2007, 109 (7): 3015-3023.PubMed

66.

Ramos-Nino ME, Blumen SR, Sabo-Attwood T, Pass H, Carbone M, Testa JR, Altomare DA, Mossman BT: HGF mediates cell proliferation of human mesothelioma cells through a PI3K/MEK5/Fra-1 pathway. Am J Respir Cell Mol Biol. 2008, 38 (2): 209-217.PubMedCentralPubMedCrossRef

67.

Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P: Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012, 367 (2): 107-114.PubMedCrossRef

68.

Wallace EM, Lyssikatos JP, Yeh T, Winkler JD, Koch K: Progress towards therapeutic small molecule MEK inhibitors for use in cancer therapy. Curr Top Med Chem. 2005, 5 (2): 215-229.PubMedCrossRef

69.

Yamaguchi T, Kakefuda R, Tajima N, Sowa Y, Sakai T: Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo. Int J Oncol. 2011, 39 (1): 23-31.PubMed

70.

Gilmartin AG, Bleam MR, Groy A, Moss KG, Minthorn EA, Kulkarni SG, Rominger CM, Erskine S, Fisher KE, Yang J: GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res. 2011, 17 (5): 989-1000.PubMedCrossRef

71.

Infante JR, Fecher LA, Falchook GS, Nallapareddy S, Gordon MS, Becerra C, DeMarini DJ, Cox DS, Xu Y, Morris SR: Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol. 2012, 13 (8): 773-781.PubMedCrossRef

72.

Kim K, Kong SY, Fulciniti M, Li X, Song W, Nahar S, Burger P, Rumizen MJ, Podar K, Chauhan D: Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. Br J Haematol. 2010, 149 (4): 537-549.PubMedCentralPubMedCrossRef

73.

Yoon J, Koo KH, Choi KY: MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy. Cancer Res. 2011, 71 (2): 445-453.PubMedCrossRef

74.

Macarulla T, Tabernero J, Cervantes A, Roselló S, Van Cutsem E, Tejpar S, Prenen H, Martinelli E, Troiani T, Campana F, Laffranchi B, Jego V, von Richter O, Ciardiello F: Phase I/II study of FOLFIRI plus the MEK1/2 inhibitor pimasertib (MSC1936369b) as second-line treatment for kras mutated metastatic colorectal cancer. Ann Oncol. 2012, 23 (Suppl 4): PD-0024-

75.

Yeh TC, Marsh V, Bernat BA, Ballard J, Colwell H, Evans RJ, Parry J, Smith D, Brandhuber BJ, Gross S: Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res. 2007, 13 (5): 1576-1583.PubMedCrossRef

76.

Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR, Hanson LJ, Gore L, Chow L, Leong S: Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008, 26 (13): 2139-2146.PubMedCentralPubMedCrossRef

77.

Bennouna J, Lang I, Valladares-Ayerbes M, Boer K, Adenis A, Escudero P, Kim TY, Pover GM, Morris CD, Douillard JY: A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens. Invest New Drugs. 2011, 29 (5): 1021-1028.PubMedCrossRef

78.

Bodoky G, Timcheva C, Spigel DR, La Stella PJ, Ciuleanu TE, Pover G, Tebbutt NC: A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. Invest New Drugs. 2012, 30 (3): 1216-1223.PubMedCrossRef

79.

Hainsworth JD, Cebotaru CL, Kanarev V, Ciuleanu TE, Damyanov D, Stella P, Ganchev H, Pover G, Morris C, Tzekova V: A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens. J Thorac Oncol. 2010, 5 (10): 1630-1636.PubMedCrossRef

80.

Hayes DN, Lucas AS, Tanvetyanon T, Krzyzanowska MK, Chung CH, Murphy BA, Gilbert J, Mehra R, Moore DT, Sheikh A: Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clin Cancer Res. 2012, 18 (7): 2056-2065.PubMedCrossRef

81.

Kirkwood JM, Bastholt L, Robert C, Sosman J, Larkin J, Hersey P, Middleton M, Cantarini M, Zazulina V, Kemsley K: Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res. 2012, 18 (2): 555-567.PubMedCentralPubMedCrossRef

82.

O’Neil BH, Goff LW, Kauh JS, Strosberg JR, Bekaii-Saab TS, Lee RM, Kazi A, Moore DT, Learoyd M, Lush RM: Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2011, 29 (17): 2350-2356.PubMedCentralPubMedCrossRef

83.

Janne PA, Shaw AT, Pereira JR, Jeannin G, Vansteenkiste J, Barrios C, Franke FA, Grinsted L, Zazulina V, Smith P: Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol. 2013, 14 (1): 38-47.PubMedCrossRef

84.

Farley J, Brady WE, Vathipadiekal V, Lankes HA, Coleman R, Morgan MA, Mannel R, Yamada SD, Mutch D, Rodgers WH: Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol. 2013, 14 (2): 134-140.PubMedCentralPubMedCrossRef

85.

Ho AL, Grewal RK, Leboeuf R, Sherman EJ, Pfister DG, Deandreis D, Pentlow KS, Zanzonico PB, Haque S, Gavane S: Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med. 2013, 368 (7): 623-632.PubMedCentralPubMedCrossRef

86.

Barrett SD, Bridges AJ, Dudley DT, Saltiel AR, Fergus JH, Flamme CM, Delaney AM, Kaufman M, LePage S, Leopold WR: The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. Bioorg Med Chem Lett. 2008, 18 (24): 6501-6504.PubMedCrossRef

87.

Sebolt-Leopold JS, Merriman R, Omer C, Tecle H, Bridges A, Klohs W, Loi C-M, Valik H, Przybranowski S, Meyer M: The biological profile of PD 0325901: A second generation analog of CI-1040 with improved pharmaceutical potential. AACR Meeting Abstracts. 2004, 2004 (1): 925-

88.

Henderson YC, Chen Y, Frederick MJ, Lai SY, Clayman GL: MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo. Mol Cancer Ther. 2010, 9 (7): 1968-1976.PubMedCentralPubMedCrossRef

89.

Lorusso PM, Adjei AA, Varterasian M, Gadgeel S, Reid J, Mitchell DY, Hanson L, DeLuca P, Bruzek L, Piens J: Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol. 2005, 23 (23): 5281-5293.PubMedCrossRef

90.

Sheth PR, Liu Y, Hesson T, Zhao J, Vilenchik L, Liu YH, Mayhood TW, Le HV: Fully activated MEK1 exhibits compromised affinity for binding of allosteric inhibitors U0126 and PD0325901. Biochemistry. 2011, 50 (37): 7964-7976.PubMedCrossRef

91.

Haura EB, Ricart AD, Larson TG, Stella PJ, Bazhenova L, Miller VA, Cohen RB, Eisenberg PD, Selaru P, Wilner KD: A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res. 2010, 16 (8): 2450-2457.PubMedCrossRef

92.

Iverson C, Larson G, Lai C, Yeh LT, Dadson C, Weingarten P, Appleby T, Vo T, Maderna A, Vernier JM: RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. Cancer Res. 2009, 69 (17): 6839-6847.PubMedCrossRef

93.

Chang Q, Chapman MS, Miner JN, Hedley DW: Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts. BMC Cancer. 2010, 10: 515-PubMedCentralPubMedCrossRef

94.

Gore L, Lewis K, Von Hoff DD, Weiss GJ, Ramanathan RK, Adjei AA, Dy GK, Ma WW, Clendeninn NJ, Leffingwell DP: Safety, pharmacokinetics, and pharmacodynamics results from a phase I trial of BAY 86–9766 (RDEA119), a MEK inhibitor, in patients with advanced cancer. ASCO Meeting Abstracts. 2011, 29 (15_suppl): 3007-

95.

Lim HY, Yen C-J, Tak W-Y, Heo J, Choi HJ, Lin C-Y, Yoon J-H, Hsu C, Rau K-M, Poon RTP: A phase II trial of MEK inhibitor BAY 86–9766 in combination with sorafenib as first-line systemic treatment for patients with unresectable hepatocellular carcinoma (HCC). ASCO Meeting Abstracts. 2012, 30 (15_suppl): 4103-

96.

Dong Q, Dougan DR, Gong X, Halkowycz P, Jin B, Kanouni T, O’Connell SM, Scorah N, Shi L, Wallace MB: Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer. Bioorg Med Chem Lett. 2011, 21 (5): 1315-1319.PubMedCrossRef

97.

von Euw E, Atefi M, Attar N, Chu C, Zachariah S, Burgess BL, Mok S, Ng C, Wong DJ, Chmielowski B: Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines. Mol Cancer. 2012, 11: 22-PubMedCentralPubMedCrossRef

98.

Finn RS, Javle MM, Tan BR, Weekes CD, Bendell JC, Patnaik A, Khan GN, Laheru D, Anderson L, Christy-Bittel JL: A phase I study of MEK inhibitor MEK162 (ARRY-438162) in patients with biliary tract cancer. ASCO Meeting Abstracts. 2012, 30 (4_suppl): 220-

99.

Bendell JC, Papadopoulos K, Jones SF, Barrett E, Guthrie K, Kass CL, Litwiler KS, Napier C, Patnaik A: Abstract B243: A phase I dose-escalation study of MEK inhibitor MEK162 (ARRY-438162) in patients with advanced solid tumors. Mol Cancer Ther. 2011, 10 (Supplement 1): B243-CrossRef

100.

Ascierto PA, Schadendorf D, Berking C, Agarwala SS, van Herpen CM, Queirolo P, Blank CU, Hauschild A, Beck JT, St-Pierre A: MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol. 2013, 14 (3): 249-256.PubMedCrossRef

101.

Martinez-Garcia M, Banerji U, Albanell J, Bahleda R, Dolly S, Kraeber-Bodere F, Rojo F, Routier E, Guarin E, Xu ZX: First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. Clin Cancer Res. 2012, 18 (17): 4806-4819.PubMedCrossRef

102.

Mala C, Neville NG, Haindl E, Buergle M, Schmalix W, Bevan P: A phase I, first-in-human single ascending dose study of the MEK inhibitor WX-554 given to healthy male subjects. ASCO Meeting Abstracts. 2010, 28 (15_suppl): e13666-

103.

Isshiki Y, Kohchi Y, Iikura H, Matsubara Y, Asoh K, Murata T, Kohchi M, Mizuguchi E, Tsujii S, Hattori K: Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agent. Bioorg Med Chem Lett. 2011, 21 (6): 1795-1801.PubMedCrossRef

104.

Leijen S, Middleton MR, Tresca P, Kraeber-Bodere F, Dieras V, Scheulen ME, Gupta A, Lopez-Valverde V, Xu ZX, Rueger R: Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors. Clin Cancer Res. 2012, 18 (17): 4794-4805.PubMedCrossRef

105.

Wong H, Vernillet L, Peterson A, Ware JA, Lee L, Martini JF, Yu P, Li C, Del Rosario G, Choo EF: Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor. Clin Cancer Res. 2012, 18 (11): 3090-3099.PubMedCrossRef

106.

Choo EF, Belvin M, Boggs J, Deng Y, Hoeflich KP, Ly J, Merchant M, Orr C, Plise E, Robarge K: Preclinical disposition of GDC-0973 and prospective and retrospective analysis of human dose and efficacy predictions. Drug Metab Dispos. 2012, 40 (5): 919-927.PubMedCrossRef

107.

Hoeflich KP, Merchant M, Orr C, Chan J, Den Otter D, Berry L, Kasman I, Koeppen H, Rice K, Yang NY: Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition. Cancer Res. 2012, 72 (1): 210-219.PubMedCrossRef

108.

LoRusso P, Shapiro G, Pandya SS, Kwak EL, Jones C, Belvin M, Musib LC, de Crespigny A, McKenzie M, Gates MR: A first-in-human phase Ib study to evaluate the MEK inhibitor GDC-0973, combined with the pan-PI3K inhibitor GDC-0941, in patients with advanced solid tumors. ASCO Meeting Abstracts. 2012, 30 (15_suppl): 2566-

109.

Wallace EM, Lyssikatos J, Blake JF, Marlow A, Greschuk J, Yeh TC, Callejo M, Marsh V, Poch G, Otten J, Hingorani G, Winski SL, Anderson DA, Lee P, Winkler J, Koch K, Davies BR, Jones DC, Logie A, Curtis NJ, Chresta CM, Smith PD, Robinson DT: AZD8330 (ARRY-424704): Preclinical evaluation of a potent, selective MEK 1/2 inhibitor currently in phase I trials. Cancer Res. 2009, AACR Annual Meeting Proceedings 2009

110.

Cohen RB, Aamdal S, Nyakas M, Cavallin M, Green D, Learoyd M, Smith I, Kurzrock R: A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies. Eur J Cancer. 2013, 49: 1521-1529.PubMedCrossRef

111.

Ponti G, Tomasi A, Pellacani G: Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma. J Hematol Oncol. 2012, 5 (1): 60-PubMedCentralPubMedCrossRef

112.

WeiSZ L, Efferth T: Polo-like kinase 1 as target for cancer therapy. Exp Hematol Oncol. 2012, 1 (1): 38-CrossRef

113.

Lamba G, Gupta R, Lee B, Ambrale S, Liu D: Current management and prognostic features for gastrointestinal stromal tumor (GIST). Exp Hematol Oncol. 2012, 1 (1): 14-PubMedCentralPubMedCrossRef

114.

Faulkner N, LoRusso PM, Guthrie T, Soria J-C, Bahleda R, Bendell JC, Infante JR, Massard C, Van Leeuwen B, Martini J-F: Abstract C197: A phase 1 safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with erlotinib in patients with advanced solid tumors. Mol Cancer Ther. 2009, 8 (Supplement 1): C197-CrossRef

115.

Infante JR, Patnaik A, Jones SF, Papadopoulos KP, Bendell JC, Rasco DW, Bellew KM, Cox DS, Durante MG, Park JJ: Abstract B128: A phase IB study of the MEK inhibitor GSK1120212 combined with everolimus in patients with solid tumors: Interim results. Mol Cancer Ther. 2011, 10 (Supplement 1): B128-CrossRef

Title: MEK and the inhibitors: from bench to bedside
Authors: Akintunde Akinleye
Muhammad Furqan
Nikhil Mukhi
Pavan Ravella
Delong Liu
Publication date: 01-12-2013
Publisher: BioMed Central
Published in: Journal of Hematology & Oncology / Issue 1/2013
Electronic ISSN: 1756-8722
DOI: https://doi.org/10.1186/1756-8722-6-27

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2013

Differential responses to genotoxic agents between induced pluripotent stem cells and tumor cell lines

Notch1 is required for hypoxia-induced proliferation, invasion and chemoresistance of T-cell acute lymphoblastic leukemia cells

Abnormal hematopoietic phenotypes in Pim kinase triple knockout mice

Role of platelet chemokines, PF-4 and CTAP-III, in cancer biology

Intensity modulated radiotherapy for sinonasal malignancies with a focus on optic pathway preservation

A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease

Keynote webinar | Spotlight on antibody–drug conjugates in cancer